Liposomal irinotecan

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]

By afschroeder • February 14, 2026

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

Jeong H, Kim BJ, Lee CK, Park I, Zang DY, Choi HJ, Lee SS, Park DH, Song TJ, Oh D, Moon SH, Kim KP, Wainberg[...]

By sjmartinez • July 7, 2024